Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. Court of Appeals Upholds Judgment in Favor of GlaxoSmithKline in Patent Infringement Case Involving Arzerra Co-Developed with Genmab A/S


Monday, 15 Jul 2013 05:55pm EDT 

Genmab A/S announced that the United States (U.S.) Court of Appeals for the Federal Circuit has declined Genentech and Biogen Idec's request for re-hearing. The court upheld its judgment in favor of GlaxoSmithKline (GSK) in the patent infringement case involving Arzerra co-developed with Genmab brought against GSK by Genentech and Biogen Idec. The lawsuit is now over unless Genentech and Biogen Idec are granted further review by the Supreme Court. 

Company Quote

47.7663
-0.0437 -0.09%
21 Aug 2014